These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical results of 9,3"-diacetylmidecamycin in the field of pediatrics (author's transl)].
    Author: Shinozaki T, Meguro H, Koike Y, Hashira S, Fujii R.
    Journal: Jpn J Antibiot; 1982 Jan; 35(1):251-60. PubMed ID: 6978413.
    Abstract:
    MOM was administered at a daily dose of 20 to 40 mg/kg q.i.d. orally to 65 pediatric patients. These consisted of 37 cases of acute feverish respiratory tract infection, 13 cases of Mycoplasma infection, 1 case of scarlet fever and 14 cases of whooping cough. Forty pathogenic bacteria were isolated from the 37 patients with acute feverish respiratory tract infection and 1 pathogenic bacteria was isolated from the patient with scarlet fever. Thirty-five of these clinical isolates disappeared as a result of MOM administration. For these 65 cases, the clinical efficacy was good in 51 cases (78.5%), fair in 5 cases (all whooping cough) and poor in 9 cases. Twelve strains of St. pyogenes were isolated from 12 cases and 3 of these isolates persisted (25%). Ten strains of S. aureus were isolated from 10 cases and 1 of these isolates persisted. Superinfection was observed in 3 cases, 2 of which were the same species. Although the clinical effect in the 40 mg/kg/day treatment group was superior to the effects in the 20 mg/kg/day and 30 mg/kg/day treatment groups, the difference was not statistically significant.
    [Abstract] [Full Text] [Related] [New Search]